Lexeo Therapeutics, Inc. (LXEO)
4.07
-0.13
(-3.10%)
USD |
NASDAQ |
Sep 21, 16:00
4.07
0.00 (0.00%)
After-Hours: 20:00
Lexeo Therapeutics Shareholders Equity (Quarterly) : 235.06M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 235.06M |
| March 31, 2026 | 231.50M |
| December 31, 2025 | 246.67M |
| September 30, 2025 | 120.83M |
| June 30, 2025 | 138.22M |
| March 31, 2025 | 88.12M |
| December 31, 2024 | 116.84M |
| September 30, 2024 | 139.33M |
| Date | Value |
|---|---|
| June 30, 2024 | 164.95M |
| March 31, 2024 | 182.95M |
| December 31, 2023 | 113.54M |
| September 30, 2023 | 22.22M |
| June 30, 2023 | 41.41M |
| March 31, 2023 | 53.85M |
| December 31, 2022 | 72.08M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 254.90M |
| Total Liabilities (Quarterly) | 19.84M |
| Debt to Equity Ratio | 0.029 |
| Current Ratio | 13.89 |
| Net Debt Paydown Yield | 0.14% |